Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Viatris Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Viatris hat ein Gesamteigenkapital von $20.0B und eine Gesamtverschuldung von $18.0B, wodurch sich der Verschuldungsgrad auf 89.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $47.3B bzw. $27.3B. Viatris Das EBIT des Unternehmens beträgt $2.1B, so dass der Zinsdeckungsgrad 3.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $1.1B.

Wichtige Informationen

89.7%

Verhältnis von Schulden zu Eigenkapital

US$17.96b

Verschuldung

Zinsdeckungsgrad	3.7x
Bargeld	US$1.11b
Eigenkapital	US$20.01b
Gesamtverbindlichkeiten	US$27.33b
Gesamtvermögen	US$47.34b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: VTRSDie kurzfristigen Aktiva des Unternehmens ($12.9B) übersteigen seine kurzfristigen Passiva ($7.8B).

Langfristige Verbindlichkeiten: VTRSDie kurzfristigen Vermögenswerte des Unternehmens ($12.9B) decken seine langfristigen Verbindlichkeiten ($19.6B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: VTRSDie Nettoverschuldung im Verhältnis zum Eigenkapital (84.2%) wird als hoch angesehen.

Schulden abbauen: VTRS Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 115.6% auf 89.7% zurückgegangen.

Schuldendeckung: VTRSDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (13.6%) gedeckt.

Zinsdeckung: Die Zinszahlungen für die Schulden von VTRS sind durch das EBIT gut gedeckt (3.7x coverage).

Viatris Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

IQuest Enterprises Private Limited acquired API operations of Viatris in India.

Viatris: Skeptics Proven Right Once Again

Chief Legal Officer recently sold US$928k worth of stock

First quarter dividend of US$0.12 announced

Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024

First quarter 2024 earnings: EPS misses analyst expectations

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Price target decreased to US$12.55

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Viatris stock rises amid potential plans for €3B sale of European OTC assets

Take These Broken Wings And Learn To Fly Again Viatris

Viatris: 5% Dividend Yield Is A Threat For Investors

Independent Non-Executive Director recently sold US$100k worth of stock

Viatris: Products, Profitability And Pipeline - The Keys To Success

Upcoming dividend of US$0.12 per share

Consensus forecasts updated

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris declares $0.12 dividend

Viatris: A Spinoff To Own